article
Uncovering the genetic and cellular impacts of smoking
Epigenetic data assessing the effects of smoking on DNA methylation could serve as biomarkers of exposure effects.
List view / Grid view
Ellen Capon (Drug Target Review)
article
Developing the next generation of antibody drug conjugates
In this Q&A, Léo Marx, Medicinal Chemistry Project Manager at Debiopharm, details how the therapeutic window of ADCs can be impacted, how we can overcome the challenges associated with achieving site-specific bioconjugation, and other essential considerations for optimising ADC performance.
article
Pioneering the advancement of pre-targeted radioimmunotherapies
Although pre-targeting is still in its infancy, it has immense potential to increase state-of-the-art radioligand therapies. In this Q&A, PreTT reveals how their pre-targeted RLTs surpass traditional methods, transforming cancer treatment.
article
Identifying vascular disease associations
In this Q&A, Associate Professor Dr Mete Civelek shares insights from the University of Virginia’s exciting recent study identifying several potential therapeutic targets for accelerating translational research in cardiovascular disease treatment, with a focus on proteins associated with the extracellular matrix (ECM) secretion by smooth muscle cells (SMCs).
article
HIF inhibition: a potential therapeutic approach for cancers
In this Q&A, Curve Therapeutic’s Chief Scientific Officer Professor Ali Tavassoli discusses how dual HIF inhibition could combat solid tumours.
article
How nucleolar stress accelerates aging in mice
Dr Fernández-Capetillo shares his insights from a recent study conducted at the CNIO, elucidating how the expression of (PR)arginine-rich peptides affects ribosomal protein translation and accumulation, and how accelerated aging can be alleviated.
article
Using AI to predict metastatic behaviour of NSCLC
Dr Richard Cote and Dr Ramaswamy Govindan of the Washington University School of Medicine elucidate how AI, particularly deep learning networks, could identify histopathologic features in non-small cell lung cancer, and impact the treatment approach for early-stage patients.
article
Investigating antipsychotics in a Parkinson’s disease psychosis model
In this Q&A, Dr Nicholas Waters, Head of R&D at IRLAB, shares how three compounds, including IRLABs Mesdopetam and an experimental dopamine D3 receptor antagonist, could reverse features associated with the psychosis-like state of Parkinson’s disease.
article
Developing an mRNA therapy for Duchenne muscular dystrophy
In this Q&A, Aki Ko, CEO and co-founder of Elixirgen Therapeutics, elucidates how their new mRNA technology could potentially restore muscle function in those suffering from Duchenne muscular dystrophy.
article
The advancement of drug-free immunotherapy
Researchers have created a neutrophil therapy, involving micropatches that maintain the cells’ antitumour state, which could offer significant clinical and commercial value.
article
Vitamin A and its role in psychiatric and other disorders
In this Q&A, Dr Murray Cairns, NHMRC Leadership Research Fellow at the University of Newcastle, shares his insights about the genetic influences on circulating retinol, and explains how a retinol polygenic score could be utilised in a precision medicine approach.
article
Streamlining the path from lab to market with 3D bioprinting
In this Q&A, Dr Vidmantas Šakalys, CEO of Vital3D, provides insights into the potential of 3D bioprinting to revolutionise the traditional drug development process, facilitating more accurate models and limiting the use of animal testing.
article
Bile acids and the microbiome: revolutionising disease approaches
Thousands of bile acids have been discovered, providing new insights into how microbes influence distant organ systems.
article
Breakthrough for pancreatic cancer treatment
Researchers have designed the first small molecule drug targeting K-Ras GD12, which could improve pancreatic cancer outcomes.
article
Scalable precision design targeting complex product profiles
We had the privilege of speaking to Dr Víctor Sebastián Pérez, Associate Director of Computational Drug Design, following his presentation at ELRIG UK 2023. He shares his insights into how Exscientia is using AI to design drug candidates for cancer treatment.